FOLH1 and prostate carcinoma: Although further in vivo antitumor investigation of Chol–PEG–DUP1–M-PTX is required, the results of our current study represent a meaningful explore in advancing the use of DUP1 peptide modified micelles as a potent strategy to treat PSMA negative prostate cancer.